Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tumor microvasculature in the liver refers to the abnormal network of small blood vessels that form within and around liver tumors, particularly hepatocellular carcinoma (HCC). This vasculature supports tumor growth, progression, invasion, and metastasis through enhanced angiogenesis. It is characterized by disorganized architecture, deficient pericyte coverage, and leaky endothelium. Targeting the aberrant microvasculature is a major therapeutic strategy in HCC, but resistance can develop. Markers such as MVD are used prognostically.
Inhibition of angiogenesis via VEGF pathway blockade; multi-kinase inhibition
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Microvasculature (Liver) (N/A).